Sotorasib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CHUIKYO (Japan), HAS (France) and NICE (England), among others, recommended or restricted sotorasib, while AOTMIT (Poland), DMC (Denmark) and NYE METODER (Norway), among others, did not recommend it.
The record spans 4.4 years, opening at AWMSG (Wales) on 7 Jan 2022 and running to 5 Jun 2026.
CIPM (Spain) changed its position: not recommended on 2 Feb 2023, recommended by 23 Nov 2023, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), which is among the eight highest-volume agencies here.
The file is active: 8 of 18 records date from 2023 or later.
Against its own class, sotorasib is an outlier: 50% of its decisive outcomes were positive, where molecules sharing ATC class L01X average 75%.
4 distinct indication wordings are recorded for sotorasib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
2 of these 18 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess sotorasib, on 7 Jan 2022; NYE METODER (Norway) did not open a file until 15 Jun 2025 — a wide spread of 3.4 years between the earliest and latest system to look at it.
Activity is concentrated rather than steady: 10 of 18 dated records fall in 2022 alone.
5 of the 12 agencies here assessed sotorasib more than once, CIPM (Spain) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
sotorasib has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for sotorasib reads 6 not recommended, 4 recommended, 2 deferred to NICE and 2 no benefit, with 4 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 15 Jun 2025 | Monoterapi for behandling av voksne med avansert ikke-småcellet lungekreft (NSCLC) med KRAS G12C-mutasjon og progresjon … | not introduced | source |
| CIPM (Spain) | 23 Nov 2023 | Indicaciones terapéuticas autorizadas: En monoterapia está indicado para el tratamiento de adultos con cáncer de pulmón … | financed by the SNS · art. 92 a | source |
| G-BA (Germany) | 3 Aug 2023 | Lumykras — benefit assessment §35a | added benefit: not proven | source |
| AOTMIT (Poland) | 14 Apr 2023 | programu lekowego „Leczenie chorych na raka płuca (ICD-10: C34) oraz międzybłoniaka opłucnej (ICD-10: C45) | not recommended | source |
| HAS (France) | 15 Jun 2022 | Listing (Transparency Committee) | ASMR V | source |
13 further decisions for sotorasib, across 10 agencies, are not shown here. They include the most recent record on file, 5 Jun 2026 from AWMSG (Wales); its outcome is in the subscriber dataset. They link to 11 further source documents.
Related molecules
- bevacizumab — divergent outcome (not recommended vs recommended) on a shared indication
- osimertinib — divergent outcome (not recommended vs recommended) on a shared indication
- selpercatinib — divergent outcome (not recommended vs recommended) on a shared indication
- entrectinib — divergent outcome (not recommended vs recommended) on a shared indication
- atezolizumab — divergent outcome (not recommended vs recommended) on a shared indication
- repotrectinib — divergent outcome (not recommended vs recommended) on a shared indication
Coverage: 18 decisions for sotorasib from 12 agencies, 2022 to 2026. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.